Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;21(2):229-234.
doi: 10.17305/bjbms.2020.4896.

The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis

Boda Guo  1 , Shengjing Liu  2 , Miao Wang  3 , Huimin Hou  3 , Ming Liu  1
Affiliations

The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis

Boda Guo et al. Bosn J Basic Med Sci. .

Abstract

It is widely accepted that renal cell carcinoma (RCC) with liver metastasis (LM) carries a dismal prognosis. We aimed to explore the value of cytoreductive nephrectomy among these patients. Patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2017. The univariate and multivariate Cox proportional hazards models were conducted to select the prognostic predictors of survival. Patients were divided into nephrectomy and non-nephrectomy groups. Propensity score-matching (PSM) analyses were applied to reduce the above factors' differences between the groups. Overall survival (OS) was compared by Kaplan-Meier analyses. Data from 683 patients were extracted from the database. The univariate Cox regression and multivariate Cox regression revealed that factors including age, histologic type, T and N stages, lung metastasis, brain metastasis, and nephrectomy were significant predictors of survival in the patients. After the PSM analyses, we found that nephrectomy prolonged OS. Nephrectomy can prolong OS in eligible RCC patients with LM.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflict of interests

Figures

FIGURE 1
FIGURE 1
The flowchart of data screening. SEER: Surveillance, Epidemiology, and End Results; TNM: Tumor-node-metastasis.
FIGURE 2
FIGURE 2
Kaplan–Meier analyses for cancer-specific survival in patients with or without nephrectomy before matching (A) and after matching (B).
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492. - PubMed
    1. Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Rosiello G, Tian Z, et al. Synchronous metastasis rates in T1 renal cell carcinoma:A surveillance, epidemiology, and end results database-based study. Eur Urol Focus. 2020;2020:30068. https://doi.org/10.1016/j.euf.2020.02.011. - PubMed
    1. Kim SH, Park WS, Park B, Pak S, Chung J. A retrospective analysis of the impact of metastasectomy on prognostic survival according to metastatic organs in patients with metastatic renal cell carcinoma. Front Oncol. 2019;9:413. https://doi.org/10.3389/fonc.2019.00413. - PMC - PubMed
    1. Gonnet A, Salabert L, Roubaud G, Catena V, Brouste V, Buy X, et al. Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments:Over 10 years of experience. BMC Cancer. 2019;19(1):1182. https://doi.org/10.1186/s12885-019-6345-2. - PMC - PubMed
    1. Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, et al. Immunotherapy in renal cell carcinoma:The future is now. Int J Mol Sci. 2020;21(7):2532. https://doi.org/10.3390/ijms21072532. - PMC - PubMed

MeSH terms